Document Type: Original Article

Authors

Department of Basic Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran

10.22034/ivsa.2020.189763.1186

Abstract

Objective- Medicinal plants and their active constituents are frequently used components for treating hyperglycemia. In the present study, the effect of curcumin was investigated on acute hyperglycemia and hyperinsulinemia induced by ketamine-xylazine in rats. To explore the possible mechanism, yohimbine (an α2-adrenergic receptor antagonist) was also used.
Design- An experimental study.
Animals– Forty-eight healthy male Wistar rats. 
Procedures– Rats were divided into eight groups with six rats in each group to receive intraperitoneal injection of normal saline, oral administration of curcumin (12.5, 50 and 200 mg/kg), intraperitoneal injection of yohimbine (0.5 and 2 mg/kg), and oral administration of curcumin (12.5 mg/kg) plus intraperitoneal injection of yohimbine (0.5 mg/kg). After these treatments, ketamine (100 mg/kg) and xylazine (10 mg/kg) were intraperitoneally administered to all groups. Blood glucose concentration was measured at 60 and 5 min before and at, 30, 60, 90 and 120 min after ketamine-xylazine injection. Serum insulin concentration was measured by ELISA kit at the end of experiment.
Results- Ketamin-xylazine increased blood glucose and decreased serum insulin. Curcumin lowered increased blood glucose and increased decreased serum insulin. Yohimbine prevented the hyperglycemia and hypoinsulinemia induced by ketamin-xylazine produced the same results as curcumin. Low doses of curcumin and yohimbine induced documented hypoglycemic and hyperinsulinemic effects.
Conclusion and Clinical Relevance- Based on the results, it is concluded that curcumin improves hyperglycemia and hypoinsulinemia induced by ketamine- xylazine and α2-adrenergic receptor may involve in this effect.

Keywords

Main Subjects

  1. Merry AF, Mitcell SJ. Complications of anaesthesia. Anaesthesia, 2018; 73: 7-11.
  2. Veilleux-Lemieux D, Castel A, Carrier D, Beaudry F, Vachon P. Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. Journal of the American Association for Laboratory Animal Science, 2013; 52: 567-570.
  3. Dugassa J, Fromsa A. Review on dissociative anaesthetics and compatible drug combinations in veterinary clinical practice. Veterinary Medicine, 2018; 3: 21-30.
  4. Davis JA. Mouse and rat anesthesia and analgesia. Current Protocols in Neurosciences 2008; 42: 1-21.
  5. Saha JK, Xia J, Grondin JM, Engle SK, Jakubowski JA. Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models. Experimental Biology and Medicine (Maywood), 2005; 230: 777-784.
  6. Erfanparast A, Tamaddonfard E, Mohammadi E, Mohammadi A. Effect of vitamine B12 on acute model of hyperglycemia induced by ketamine xylazine in rats. Urmia Medical Journal, 2017; 28: 28-38.
  7. Zhou H, Beevers CS, Huang S. The targets of curcumin. Current Drug Targets 2011; 12: 332-347.
  8. Ghorbani Z, Hekmatdoost A, Mirmiran P. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. International Journal Endocrinology and Metabolism, 2014; 12: e18081.
  9. Kulkarni S, Dhir A, Akula KK. Potentials of curcumin as an antidepressant. Scientific World Journal, 2009; 9: 1233-1241.
  10. Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Experimental and Molecular Medicine, 2016; 48: e219.
  11. Chandra R, Liddle RA. Modulation of pancreatic exocrine and endocrine secretion. Current Opinion in Gastroenterology, 2013; 29: 517-522.
  12. Cabral AD, Kapusta DR, Kenigs VA, Varner KJ. Central alpha2-receptor mechanisms contribute to enhanced renal responses during ketamine-xylazine anesthesia. American Journal of Physiology, 1998; 275: 1867-1874.
  13. Tamaddonfard E, Erfanparast A, Hamzeh-Gooshchi N, Yousofizadeh S. Effect of curcumin, the active constituent of turmeric, on penicillin-induced epileptiform activity in rats Avicenna Journal of Phytomedicine, 2012; 2: 196-205.
  14. Moradi-Arzeloo M, Farshid AA, Tamaddonfard E, Asri-Rezaei S. Effects of histidine and vitamin C on isoproterenol-induced acute myocardial infarction in rats. Veterinary Research Forum, 2016; 7: 47-54.
  15. Taati M, Tamaddonfard E. Ventrolateral orbital cortex oxytocin attenuates neuropathic pain through periaqueductal gray opioid receptor. Pharmacological Reports, 2018; 70: 577-583.
  16. Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesthesia and Essays Research, 2014; 8: 283-290.
  17. Tyler MW, Yourish HB, Ionescu DF, Haggarty SJ. Classics in chemical neuroscience: ketamine. ACS Chemical Neuroscience, 2017; 8: 1122-1134
  18. Greene SA, Thurmon JC. Xylazine - a review of its pharmacology and use in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics, 1988; 11: 295-313.
  19. Fagerholm V, Haaparanta M, Scheinin M.  α2-adrenoceptor regulation of blood glucose homeostasis. Basic and Clinical Pharmacology and Toxicology, 2011; 108: 365-370.
  20. Kitano T, Kobayashi T, Yamaguchi S, Otsuguro KI. The α2A -adrenoceptor subtype plays a key role in the analgesic and sedative effects of xylazine. Journal of Veterinary Pharmacology and Therapeutics, 2019; 42: 243-247.
  21. Singh A, Gibert Y, Dwyer KM. The adenosine, adrenergic and opioid pathways in the regulation of insulin secretion, beta cell proliferation and regeneration. Pancreatology, 2018; 18: 615-623.
  22. Restitutti F, Raekallio M, Vainionpää M, Kuusela E, Vainio O. Plasma glucose, insulin, free fatty acids, lactate and cortisol concentrations in dexmedetomidine-sedated dogs with or without MK-467: a peripheral α-2 adrenoceptor antagonist. Veterinary Journal, 2012; 193: 481-485.
  23. Kato M, Nishikawa S, Ikehata A, Dochi K, Tani T, Takahashi T, Imaizumi A, Tsuda T. Curcumin improves glucose tolerance via stimulation of glucagon-like peptide-1 secretion. Molecular Nutrition & Food Research, 2017; 61: 3.
  24. Abdel Aziz MT, El-Asmar MF, El Nadi EG, Wassef MA, Ahmed HH, Rashed LA, Obaia EM, Sabry D, Hassouna AA, Abdel Aziz AT. The effect of curcumin on insulin release in rat-isolated pancreatic islets. Angiology, 2010; 61: 557-566.
  25. Parmar MS, Syed I, Gray JP, Ray SD. Curcumin, hesperidin, and rutin selectively interfere with apoptosis signaling and attenuate streptozotocin-induced oxidative Stress-mediated hyperglycemia. Current Neurovascular Research, 2015; 12: 363-374.
  26. Meghana K, Sanjeev G, Ramesh B. Curcumin prevents streptozotocin-induced islet damage by scavenging free radicals: a prophylactic and protective role. Euroupean Journal of Pharmacology, 2007; 577: 183-191.
  27. Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, Li XX, Sun CH. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Molecular Nutrition & Food Research, 2013; 57: 1569-1577.
  28. Dewar AM, Clark RA, Singer AJ, Frame MD. Curcumin mediates both dilation and constriction of peripheral arterioles via adrenergic receptors. Journal of Investigative Dermatology, 2011; 131: 1754-1760.
  29. Cheng TC, Lin CS, Hsu CC, Chen LJ, Cheng KC, Cheng JT. Activation of muscarinic M-1 cholinoceptors by curcumin to increase glucose uptake into skeletal muscle isolated from Wistar rats. Neuroscience Letter, 2009; 465: 238-241.
  30. Boozari M, Butler AE, Sahebkar A. Impact of curcumin on toll-like receptors. Journal of Cellular Physiology, 2019; 234: 12471-12482.
  31. Cheng YF, Guo L, Xie YS, Liu YS, Zhang J, Wu QW, Li JM. Curcumin rescues aging-related loss of hippocampal synapse input specificity of long term potentiation in mice. Neurochemical Research, 2013; 38: 98-107.